User login
Key clinical point: Pyrotinib+capecitabine showed intracranial objective response and was well tolerated in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC) and brain metastases in the PERMEATE phase 2 study.
Major finding: The intracranial objective response rate was 74.6% (95% CI 61.6%-85.0%) in radiotherapy-naive patients and 42.1% (95% CI 20.3%-66.5%) in patients with progressive disease after whole-brain radiotherapy. Common grade 3 treatment-emergent adverse events were diarrhea and decreased white blood cell count. No treatment-related deaths were reported.
Study details: Findings are from the single-arm, phase 2 PERMEATE study including 78 patients with HER2+ BC and brain metastases who were either radiotherapy-naive or had progressive disease after radiotherapy. Patients received 400 mg pyrotinib once daily and 1000 mg/m2 capecitabine twice daily for 14 days, followed by 7 days off during each 21-day cycle.
Disclosures: This study was funded by the National Cancer Centre Climbing Foundation Key Project of China and Jiangsu Hengrui Pharmaceuticals. The authors declared no conflicts of interest.
Source: Yan M et al. Lancet Oncol. 2022 (Jan 24). Doi: 10.1016/S1470-2045(21)00716-6.
Key clinical point: Pyrotinib+capecitabine showed intracranial objective response and was well tolerated in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC) and brain metastases in the PERMEATE phase 2 study.
Major finding: The intracranial objective response rate was 74.6% (95% CI 61.6%-85.0%) in radiotherapy-naive patients and 42.1% (95% CI 20.3%-66.5%) in patients with progressive disease after whole-brain radiotherapy. Common grade 3 treatment-emergent adverse events were diarrhea and decreased white blood cell count. No treatment-related deaths were reported.
Study details: Findings are from the single-arm, phase 2 PERMEATE study including 78 patients with HER2+ BC and brain metastases who were either radiotherapy-naive or had progressive disease after radiotherapy. Patients received 400 mg pyrotinib once daily and 1000 mg/m2 capecitabine twice daily for 14 days, followed by 7 days off during each 21-day cycle.
Disclosures: This study was funded by the National Cancer Centre Climbing Foundation Key Project of China and Jiangsu Hengrui Pharmaceuticals. The authors declared no conflicts of interest.
Source: Yan M et al. Lancet Oncol. 2022 (Jan 24). Doi: 10.1016/S1470-2045(21)00716-6.
Key clinical point: Pyrotinib+capecitabine showed intracranial objective response and was well tolerated in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC) and brain metastases in the PERMEATE phase 2 study.
Major finding: The intracranial objective response rate was 74.6% (95% CI 61.6%-85.0%) in radiotherapy-naive patients and 42.1% (95% CI 20.3%-66.5%) in patients with progressive disease after whole-brain radiotherapy. Common grade 3 treatment-emergent adverse events were diarrhea and decreased white blood cell count. No treatment-related deaths were reported.
Study details: Findings are from the single-arm, phase 2 PERMEATE study including 78 patients with HER2+ BC and brain metastases who were either radiotherapy-naive or had progressive disease after radiotherapy. Patients received 400 mg pyrotinib once daily and 1000 mg/m2 capecitabine twice daily for 14 days, followed by 7 days off during each 21-day cycle.
Disclosures: This study was funded by the National Cancer Centre Climbing Foundation Key Project of China and Jiangsu Hengrui Pharmaceuticals. The authors declared no conflicts of interest.
Source: Yan M et al. Lancet Oncol. 2022 (Jan 24). Doi: 10.1016/S1470-2045(21)00716-6.